ArticleThoracic cancer2021

Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report.

Jun Ni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.